ACALABRUTINIB
acalabrutinib 100 mg tablet, 56
ACALABRUTINIB (15354D)
15354D
Manner of administration:Oral
Restriction
Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Treatment phase: Continuing treatment (treatment cycles 3 to 14 inclusive) of first-line therapy -
in combination with venetoclax
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 56 | # of repeats: 5 | DPMQ: $7,052.30 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| CALQUENCE | |||||